Ras (Kras or Nras) Gene Mutation clinical trials at University of California Health

2 research studies open to eligible people

Showing trials for

  • NST-628 Oral Tablets in Subjects With Solid Tumors

    open to eligible people ages 18 years and up

    This is a two-part Phase 1, open label, multi-center, single arm, non-randomized, multiple dose, safety, pharmacokinetic (PK) and preliminary efficacy study of single agent NST-628 in adult patients with MAPK pathway mutated/dependent advanced solid tumors who have exhausted standard treatment options.

    at UCLA UCSF

  • IK-595 in RAS- or RAF-altered Advanced Tumors

    open to eligible people ages 18 years and up

    This is a Phase 1, FIH, Dose Escalation and Dose Expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) effects, and preliminary antitumor activity of IK-595, a MEK/RAF molecular glue, administered orally as monotherapy in patients with advanced solid tumors with gene alterations in the RAS- MAPK pathway for whom there are no further treatment options known to confer clinical benefit.

    at UC Irvine

Our lead scientists for Ras (Kras or Nras) Gene Mutation research studies include .

Last updated: